Skip to main content
. 2021 Apr 13;6(16):10506–10514. doi: 10.1021/acsomega.0c03262

Figure 3.

Figure 3

Validation analysis of the candidate proteins. Immunoblots of TBB2C and VIM. (A) Relative expression of TBB2C in different OC stages compared to benign controls and healthy subjects (ns, non significant; *p-value, 0.01; ***p-value, 0.0004; ****p-value < 0.0001). (B) ROC curve displaying TBB2C sensitivity to distinguish OC from benign controls and healthy subjects, and benign controls from healthy subjects (C).